This study investigates the association of surrogate molecular subtypes with survival outcomes and recurrence in a cohort of Swedish women treated for small, lymph node negative BC between 1986–2004, a time period before multimodal treatment protocols were routine and before HER2-targeted therapy was approved for adjuvant BC treatment in Sweden. This evidence concerns the gene ERBB2 and breast cancer.